A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Study Number

4205224

Phase

III

Age Group

Adult

Principal Investigator

Saby George

Purpose

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

Check your eligibility for this trial

Check now

Full Title

CA071-1000: A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus a Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)- rechARge

ClinicalTrials.Gov ID

NCT06764485

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.